Cardiometabolic
Cardiometabolic research targets the cluster of conditions linking metabolic dysfunction to cardiovascular outcomes: dyslipidemia, hypertension, insulin resistance, hepatic steatosis (NAFLD/NASH), and the broader metabolic syndrome. Incretin agonists have shown cardiovascular outcome benefits in major trials (SELECT for the long-acting GLP-1 agonist). Tesamorelin shows benefits in HIV-associated dyslipidemia and NAFLD.
